Wellington Management Group LLP cut its stake in Evotec SE (NASDAQ:EVO - Free Report) by 12.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,299,905 shares of the company's stock after selling 334,529 shares during the quarter. Wellington Management Group LLP owned approximately 0.65% of Evotec worth $9,568,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of EVO. BNP Paribas Financial Markets bought a new stake in Evotec in the fourth quarter worth $27,000. CSS LLC IL bought a new stake in Evotec in the fourth quarter worth $50,000. Bank of America Corp DE boosted its holdings in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after purchasing an additional 9,289 shares in the last quarter. Lighthouse Investment Partners LLC bought a new stake in Evotec in the fourth quarter worth $166,000. Finally, DCF Advisers LLC boosted its holdings in Evotec by 5.9% in the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after purchasing an additional 12,816 shares in the last quarter. 5.81% of the stock is owned by institutional investors and hedge funds.
Evotec Stock Performance
Shares of NASDAQ:EVO traded up $0.07 on Wednesday, hitting $4.10. 223,940 shares of the company were exchanged, compared to its average volume of 132,320. The company's 50 day moving average price is $3.81 and its two-hundred day moving average price is $4.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. Evotec SE has a one year low of $2.84 and a one year high of $5.64.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on EVO. Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th. Royal Bank of Canada reaffirmed an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $5.93.
Get Our Latest Report on EVO
Evotec Profile
(
Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
